Acuren is trading at $7.37 (up 7.6%) in pre-market, rebounding from recent weakness observed over the past week.

  • The upward move follows recent coverage and price-target activity from major analysts, including Jefferies and UBS.
  • Investors are closely monitoring ongoing NV5 merger integration and guidance discussions, though no fresh company-specific news has been reported for July 20, 2026.